Surrozen Receives FDA Clearance to Begin Clinical Development of DME Treatment
Surrozen has received FDA clearance for its Investigational New Drug (IND) application, allowing it to advance SZN-8141 into clinical development. The bifunctional antibody is intended as a treatment for diabetic macular edema (DME), a serious complication of diabetes that can lead to vision loss. This regulatory milestone marks an important step in Surrozen's pipeline and could position the company to enter a significant unmet medical need within ophthalmology. SZN-8141 is designed to target two pathways simultaneously, potentially offering improved therapeutic outcomes compared to existing treatments for DME.
Tickers: $SRZN
Topics: bifunctional antibody clinical development diabetic macular edema